These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29116406)

  • 1. A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.
    Tischer B; Bilang M; Kraemer M; Ronga P; Lacouture ME
    Support Care Cancer; 2018 Apr; 26(4):1169-1179. PubMed ID: 29116406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
    Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
    Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients' Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers.
    Kafatos G; Dube S; Burdon P; Demonty G; Flinois A; Leclerc M; Lowe K; Feudjo-Tepie M; Segaert S
    Clin Colorectal Cancer; 2020 Jun; 19(2):100-108.e9. PubMed ID: 32113902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.
    Tischer B; Huber R; Kraemer M; Lacouture ME
    Support Care Cancer; 2017 Feb; 25(2):651-660. PubMed ID: 27718067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer.
    Annunziata MC; De Stefano A; Fabbrocini G; Leo S; Marchetti P; Romano MC; Romano I
    Clin Drug Investig; 2019 Sep; 39(9):825-834. PubMed ID: 31264159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy].
    Matzka M; Stöhr D; Colditz A; Köck-Hódi S; Koller M; Mayer H
    Pflege; 2017 Jan; 30(1):9-17. PubMed ID: 27901405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
    Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
    Lacouture ME; Maitland ML; Segaert S; Setser A; Baran R; Fox LP; Epstein JB; Barasch A; Einhorn L; Wagner L; West DP; Rapoport BL; Kris MG; Basch E; Eaby B; Kurtin S; Olsen EA; Chen A; Dancey JE; Trotti A
    Support Care Cancer; 2010 Apr; 18(4):509-22. PubMed ID: 20145956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study.
    Tseng LC; Chen KH; Wang CL; Weng LC
    Medicine (Baltimore); 2020 Jun; 99(23):e20510. PubMed ID: 32501998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' and physicians' gender and perspective on shared decision-making: A cross-sectional study from Dubai.
    Alameddine M; Otaki F; Bou-Karroum K; Du Preez L; Loubser P; AlGurg R; Alsheikh-Ali A
    PLoS One; 2022; 17(9):e0270700. PubMed ID: 36048748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
    Sun W; Li J
    Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.
    Kim YS; Ji JH; Oh SY; Lee S; Huh SJ; Lee JH; Song KH; Son CH; Roh MS; Lee GW; Lee J; Kim ST; Kim CK; Jang JS; Hwang IG; Ahn HK; Park LC; Oh SY; Kim SG; Lee SC; Lim DH; Lee SI; Kang JH
    Oncologist; 2020 Jan; 25(1):e186-e193. PubMed ID: 31492766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment.
    Saito Y; Uchiyama K; Takekuma Y; Komatsu Y; Sugawara M
    Support Care Cancer; 2023 Aug; 31(8):504. PubMed ID: 37528282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin toxicities associated with epidermal growth factor receptor inhibitors.
    Li T; Perez-Soler R
    Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.
    Hofheinz RD; Deplanque G; Komatsu Y; Kobayashi Y; Ocvirk J; Racca P; Guenther S; Zhang J; Lacouture ME; Jatoi A
    Oncologist; 2016 Dec; 21(12):1483-1491. PubMed ID: 27449521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between quality of life and skin toxicities of epidermal growth factor receptor inhibitors in cancer patients: A literature review.
    Hirayama K; Su Y; Chiba M; Izutsu M; Yuki M
    Jpn J Nurs Sci; 2020 Jul; 17(3):e12321. PubMed ID: 31930679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk communication in rheumatoid arthritis.
    Fraenkel L; Bogardus S; Concato J; Felson D
    J Rheumatol; 2003 Mar; 30(3):443-8. PubMed ID: 12610798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors.
    Peng Y; Li Q; Zhang J; Shen W; Zhang X; Sun C; Cui H
    Biosci Trends; 2019 Jan; 12(6):537-552. PubMed ID: 30555112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR Targeting TKI-Related Skin Toxicities in a Patient with Darker Skin: A Case Report.
    Zereshkian A; Thawer A; Hwang DM; Cheng S
    Curr Oncol; 2022 Apr; 29(4):2509-2515. PubMed ID: 35448179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.
    Basse C; Chabanol H; Bonte PE; Fromantin I; Girard N
    Lung Cancer; 2022 Nov; 173():116-123. PubMed ID: 36198244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.